During Biotech Showcase Digital, registered conference participants will be able to watch a pre-recorded presentation by BioEclipse. Also, Dr. Contag will host virtual one-on-one meetings with registered investors and pharmaceutical and biotechnology companies via the conference s networking and scheduling platform, partneringONE®, to discuss BioEclipse s business and highlight recent corporate achievements, as well as anticipated milestones in the clinical program for CRX100. BioEclipse has initiated an open-label, Phase 1 dose-escalation study to evaluate the safety, tolerability, and pharmacokinetic (PK) properties of CRX100 in advanced solid tumors that do not respond to standard of care, including triple-negative breast cancer, colorectal cancer, hepatocellular carcinoma, osteosarcoma, epithelial ovarian cancer, and gastric cancer.
„Soap for Future : Hürther Schüler verkaufen nachhaltige Produkte
ksta.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksta.de Daily Mail and Mail on Sunday newspapers.
„Soap for Future : Hürther Schüler verkaufen nachhaltige Produkte
rundschau-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rundschau-online.de Daily Mail and Mail on Sunday newspapers.
V2ACT Therapeutics™, LLC Announces FDA Clearance of an IND Application to proceed with a Phase 1/2a Study of V2ACT for the Treatment of Pancreatic Cancer
- V2ACT Therapeutics™, LLC is a joint venture of Genelux Corporation and TVAX Biomedical, Inc.
- V2ACT is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic immunotherapy) and V-ACT (vaccine-enhanced adoptive cell therapy).
- V2ACT capitalizes on:
- Olvi-Vec as an ideal systemic immunomodulator with its excellent safety profile, favorable immune activation effects on the tumor microenvironment and well-documented anti-cancer effects on a wide range of cancers demonstrated in preclinical and phase 2 clinical studies.